Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

This early-stage study tests a new drug called FXS887 in 14 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can help control the cancer. Participants will recei…

This study tests a combination of two drugs, luvometinib and anlotinib, in people with a specific type of advanced lung cancer (KRAS-mutated non-small cell lung cancer) that has worsened after prior treatment. The goal is to see if the combo can shrink tumors. About 48 adults age…

This early-stage study tests a new drug called FXB0871 in about 138 adults with advanced solid tumors, including lung and liver cancers that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study is not yet…

This study tests a new drug called FXS6837 for people with IgA nephropathy, a kidney disease. About 60 adults will receive either the drug or a placebo to see if it reduces protein in the urine, a sign of kidney damage. The goal is to control the disease and protect kidney functi…